{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T05:49:06Z","timestamp":1776923346905,"version":"3.51.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Differentiated thyroid cancer accounts for the majority of thyroid cancers and has a good prognosis after standard treatment. However, there are still some complex and refractory thyroid cancers, including locally advanced differentiated thyroid carcinoma and medullary carcinoma (MTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic thyroid carcinoma (ATC). Here, we report the therapeutic response of 2 advanced thyroid carcinoma patients treated with dabrafenib and trametinib.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Two elderly females presented to the clinic with neck masses, dyspnea, and dysphagia. Signs of the trachea and esophageal compression were markedly visible in computed tomography (CT) scan and ultrasonography. Pathologic diagnoses of PDTC were confirmed for both patients through ultrasound-guided fine-needle aspiration (US-FNA). Both patients were significantly relieved from dyspnea and dysphagia after a course of treatment with dabrafenib and trametinib, and their tumors gradually shrank during the follow-up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Overall, this treatment modality is rare, but effective. By sharing these 2 case reports, we hope to provide a reference for the treatment of clinically similar patients with advanced thyroid carcinoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1099268","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T17:40:27Z","timestamp":1672940427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case report: Visibly curative effect of dabrafenib and trametinib on advanced thyroid carcinoma in 2 patients"],"prefix":"10.3389","volume":"12","author":[{"given":"Xue","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0509","article-title":"Poorly differentiated carcinoma of the thyroid gland: Current status and future prospects","volume":"29","author":"Ibrahimpasic","year":"2019","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831115)52:10<1849::aid-cncr2820521015>3.0.co;2-x","article-title":"Poorly differentiated carcinoma of the thyroid. a clinicopathologic entity for a high-risk group of papillary and follicular carcinomas","volume":"52","author":"Sakamoto","year":"1983","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-007-9033-3","article-title":"An evidence-based review of poorly differentiated thyroid cancer","volume":"31","author":"Sanders","year":"2007","journal-title":"World J Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.3390\/jcm10225258","article-title":"Poorly differentiated thyroid carcinoma: Single centre experience and review of the literature","volume":"10","author":"Bellini","year":"2021","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21803","article-title":"The concepts in poorly differentiated carcinoma of the thyroid: A review article","volume":"103","author":"Nambiar","year":"2011","journal-title":"J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2020.03.003","article-title":"Poorly differentiated thyroid carcinoma","volume":"37","author":"Xu","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/107327480601300206","article-title":"Poorly differentiated and anaplastic thyroid cancer","volume":"13","author":"Patel","year":"2006","journal-title":"Cancer Control"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2020.11.008","article-title":"Clinicopathological characteristics and prognosis of poorly differentiated thyroid carcinoma diagnosed according to the Turin criteria","volume":"27","author":"Huang","year":"2021","journal-title":"Endocr Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-05898-9","article-title":"Poorly differentiated thyroid carcinoma (Pdtc) characteristics and the efficacy of radioactive iodine (Rai) therapy as an adjuvant treatment in a tertiary cancer care center","volume":"277","author":"Thiagarajan","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"Care guidelines for case reports: Explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0095-2","article-title":"Dabrafenib: First global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with mek inhibition in braf-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral mek inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0089","article-title":"Nccn guidelines insights: Thyroid carcinoma, version 2.2018","volume":"16","author":"Haddad","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0106","article-title":"Intermittent dosing of dabrafenib and trametinib in metastatic Braf(V600e) mutated papillary thyroid cancer: Two case reports","volume":"27","author":"White","year":"2017","journal-title":"Thyroid"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0642","article-title":"Fda approval summary: Dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring braf V600e mutations","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.4067\/S0034-98872020001101684","article-title":"Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. report of one case","volume":"148","author":"Finsterer","year":"2020","journal-title":"Rev Med Chil"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1099268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T17:40:31Z","timestamp":1672940431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1099268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":18,"alternative-id":["10.3389\/fonc.2022.1099268"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1099268","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"article-number":"1099268"}}